AstraZeneca Licenses Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
News Feb 10, 2009
AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds.
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.
Comments | 0 ADD COMMENT
Pfizer, Scripps Partner on DNA-Encoded Library Tech
News Jan 11, 2017